ERBB2 and breast carcinoma: VLPs for a breast cancer vaccine have been produced by genetically fusing the SpyTag/SpyCatcher to the N- or C-terminus of the Acinetobacter phage AP205 capsid protein, which auto-assembled in stable VLPs expressing multiple SpyCatcher/SpyTags per each capsid protein and an irreversible conjugation of the HER-2 extracellular domain (subdomain I-IV) on the VLP [100,111].